EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Denali Therapeutics Inc. (DNLI) had EBIT Margin of -3622.11% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$3.60M |
|
$-127.55M |
|
$0.09M |
|
$3.51M |
|
$134.15M |
|
$-130.54M |
|
$2.99M |
|
$-127.55M |
|
$-127.55M |
|
$-127.55M |
|
$-127.55M |
|
$-127.55M |
|
$-127.55M |
|
$-130.54M |
|
$-128.42M |
|
187.31M |
|
187.31M |
|
$-0.68 |
|
$-0.68 |
|
| Balance Sheet Financials | |
$753.93M |
|
$49.93M |
|
$404.03M |
|
$1.16B |
|
$90.08M |
|
$5.48M |
|
$232.69M |
|
$322.78M |
|
$835.18M |
|
$799.93M |
|
$835.18M |
|
159.76M |
|
| Cash Flow Statement Financials | |
$-228.21M |
|
$-9.62M |
|
$234.03M |
|
$208.43M |
|
$204.64M |
|
$-3.80M |
|
$46.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.37 |
|
-- |
|
-- |
|
0.01 |
|
0.01 |
|
97.42% |
|
-3622.11% |
|
|
EBIT Margin |
-3622.11% |
-- |
|
-3539.21% |
|
-3539.21% |
|
$-231.48M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
0.02 |
|
0.92 |
|
98.07 |
|
-15.27% |
|
-15.95% |
|
-11.02% |
|
-15.17% |
|
$5.23 |
|
$-1.24 |
|
$-1.22 |
|